The biopharma firm maintains its 2026 revenue guidance as investors await Phase II results for its Alzheimer’s treatment candidate.
Acadia Pharmaceuticals reaffirmed its 2026 total revenue guidance of $1.22 billion to $1.28 billion. The projection remains unchanged as the company prepares for a critical Phase II readout of remlifanserin, its Alzheimer’s disease psychosis (ADP) therapy candidate.
The guidance aligns with prior disclosures and reflects investor focus on the upcoming trial data, which could influence future revenue streams. Analysts had largely expected the company to hold its forecast steady ahead of the results.
Shares showed muted movement in after-hours trading, with markets awaiting further clarity on the drug’s potential impact.